ARAY
Accuray Incorporated NASDAQ Listed Feb 8, 2007$0.29
Mkt Cap $34.9M
52w Low $0.28
0.7% of range
52w High $2.10
50d MA $0.44
200d MA $1.02
P/E (TTM)
-30.1x
EV/EBITDA
12.8x
P/B
0.6x
Debt/Equity
2.2x
ROE
-33.5%
P/FCF
-24.9x
RSI (14)
—
ATR (14)
—
Beta
1.32
50d MA
$0.44
200d MA
$1.02
Avg Volume
1.3M
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
1240 Deming Way · Madison, WI 53717-1954 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.05 | -0.09 | -80.0% | 0.48 | -25.4% | -38.6% | — | — | — | — | — |
| Feb 4, 2026 | AMC | -0.11 | -0.11 | -2.2% | 0.76 | -14.1% | -20.7% | +3.3% | -6.8% | -4.0% | -7.7% | — |
| Nov 5, 2025 | AMC | -0.01 | -0.18 | -1700.0% | 1.45 | -11.7% | -15.9% | -4.1% | +0.0% | +0.0% | +0.9% | — |
| Aug 13, 2025 | AMC | 0.03 | 0.01 | -65.7% | 1.49 | -2.7% | -2.0% | -4.1% | +15.7% | -6.8% | +0.0% | — |
| Apr 30, 2025 | AMC | -0.05 | -0.01 | +80.0% | 1.55 | -0.6% | -12.9% | +1.5% | -4.4% | -0.8% | +4.6% | — |
| Feb 5, 2025 | AMC | -0.01 | 0.02 | +300.0% | 2.49 | +4.4% | +8.0% | -9.7% | +0.8% | -6.5% | -2.6% | — |
| Nov 6, 2024 | AMC | -0.03 | -0.04 | -24.6% | 2.03 | -6.4% | +3.0% | +2.9% | -7.9% | -3.5% | -5.2% | — |
| Sep 19, 2024 | AMC | — | 0.03 | — | 1.90 | +0.0% | -8.9% | +2.3% | +0.0% | -4.0% | +2.9% | — |
| Aug 14, 2024 | AMC | 0.04 | 0.03 | -25.0% | 1.43 | +23.8% | +51.7% | +5.5% | +2.6% | -3.4% | +9.7% | — |
| May 1, 2024 | AMC | -0.01 | -0.06 | -380.0% | 2.17 | -16.1% | -29.0% | +5.2% | +10.5% | -2.2% | -4.6% | — |
| Jan 31, 2024 | AMC | -0.07 | -0.10 | -42.9% | 2.59 | +0.4% | -1.2% | -4.3% | -2.9% | +8.4% | -4.3% | — |
| Nov 7, 2023 | AMC | -0.02 | -0.03 | -40.1% | 2.73 | +5.1% | -2.6% | -8.3% | +1.2% | +3.2% | +5.1% | — |
| Aug 9, 2023 | AMC | -0.01 | -0.03 | -400.0% | 3.60 | +3.1% | -12.5% | -2.2% | +2.3% | -2.2% | -5.5% | — |
| Apr 26, 2023 | AMC | 0.00 | 0.01 | +185.7% | 2.70 | +5.9% | +17.4% | +5.4% | +3.6% | -5.8% | +8.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7 | BTIG Research | Downgrade | Buy → Neutral | — | $0.48 | $0.36 | -25.4% | -38.6% | +29.6% | — | — | — |
| Feb 5 | BTIG | Maintains | Buy → Buy | — | $0.76 | $0.65 | -14.1% | -20.7% | +3.3% | -6.8% | -4.0% | -7.7% |
| Nov 6 | BTIG | Maintains | Buy → Buy | — | $1.45 | $1.28 | -11.7% | -15.9% | -4.1% | +0.0% | +0.0% | +0.9% |
| Aug 14 | BTIG | Maintains | Buy → Buy | — | $1.49 | $1.45 | -2.7% | -2.0% | -4.1% | +15.7% | -6.8% | +0.0% |
| Oct 4 | B. Riley Securities | Maintains | Buy → Buy | — | $2.60 | $2.65 | +1.9% | +11.2% | +6.6% | -2.9% | -3.7% | +1.4% |
| Aug 31 | B. Riley Securities | Maintains | Buy → Buy | — | $2.46 | $2.46 | +0.0% | -3.3% | +1.3% | -2.1% | -2.1% | +4.3% |
| Jun 24 | BTIG | Maintains | Buy → Buy | — | $2.14 | $2.16 | +0.9% | -3.7% | +2.4% | -5.2% | +1.0% | -3.0% |
| Jun 23 | B. Riley Securities | Maintains | Buy → Buy | — | $1.92 | $2.06 | +7.3% | +11.5% | -3.7% | +2.4% | -5.2% | +1.0% |
| Dec 22 | Loop Capital | Maintains | Buy → Buy | — | $4.78 | $4.80 | +0.4% | +4.2% | -1.8% | -1.2% | -0.8% | +0.4% |
| Jan 21 | BTIG | Upgrade | Neutral → Buy | — | $3.28 | $3.70 | +12.8% | +11.6% | +7.9% | +0.8% | -1.3% | -4.1% |
| Jan 21 | BTIG Research | Upgrade | Neutral → Buy | — | $3.28 | $3.70 | +12.8% | +11.6% | +7.9% | +0.8% | -1.3% | -4.1% |
| Nov 1 | Citigroup | Upgrade | Sell → Neutral | — | $4.49 | $4.21 | -6.2% | +4.5% | +1.3% | +0.8% | +1.9% | +7.4% |
| Aug 17 | Citigroup | Maintains | Sell → Sell | — | $3.52 | $3.85 | +9.2% | +9.9% | +0.0% | +3.2% | +2.5% | -2.4% |
| Dec 19 | JP Morgan | Downgrade | Neutral → Underweight | — | $4.30 | $4.30 | +0.0% | -5.8% | +2.5% | +4.8% | -2.3% | +4.7% |
| Dec 13 | JP Morgan | Downgrade | Neutral → Underweight | — | $5.05 | $4.80 | -5.0% | -9.9% | -2.2% | -4.5% | +1.2% | -5.8% |
| Nov 30 | Lake Street | Maintains | Buy → Buy | — | $5.20 | $5.30 | +1.9% | -1.0% | +1.9% | -1.9% | -4.9% | -1.0% |
| Aug 23 | Jefferies | Maintains | Buy → Buy | — | $4.05 | $3.80 | -6.2% | +1.2% | -1.2% | +1.2% | +1.2% | -2.4% |
| Feb 6 | Aegis Capital | Maintains | Buy → Buy | — | $5.60 | $5.70 | +1.8% | +3.6% | -1.7% | -1.8% | +0.0% | +0.0% |
| Dec 14 | JP Morgan | Downgrade | Overweight → Neutral | — | $5.15 | $4.90 | -4.9% | -4.9% | +2.0% | +1.0% | -4.0% | -4.1% |
| Sep 13 | Cowen & Co. | Maintains | Outperform → Outperform | — | $5.50 | $5.61 | +2.0% | -1.1% | +0.7% | -0.4% | -0.2% | +2.6% |
| Dec 22 | RBC Capital | Maintains | Sector Perform → Perform | — | $7.12 | $7.05 | -1.0% | -1.0% | -5.5% | +0.2% | +2.4% | +1.3% |
| Nov 12 | Citigroup | Maintains | Sell → Sell | — | $7.46 | $7.18 | -3.8% | -5.5% | +0.3% | -1.4% | -2.0% | -1.6% |
| Jan 12 | Northland Securities | Maintains | Outperform → Outperform | — | $6.89 | $7.20 | +4.5% | +0.4% | -1.6% | +1.2% | -4.8% | +4.9% |
| Jun 13 | JP Morgan | Upgrade | Neutral → Overweight | — | $8.79 | $9.20 | +4.7% | +3.8% | +2.2% | +1.2% | +1.1% | -1.0% |
| Mar 11 | BTIG Research | Maintains | Buy → Buy | — | $9.72 | $9.97 | +2.6% | +0.6% | -0.5% | -0.9% | +0.6% | -0.8% |
| Jan 31 | JP Morgan | Maintains | Neutral → Neutral | — | $9.24 | $10.14 | +9.7% | +15.3% | -4.3% | +1.2% | -2.3% | -1.8% |
| Sep 20 | JP Morgan | Upgrade | Underweight → Neutral | — | $6.85 | $7.25 | +5.8% | +3.9% | +0.6% | -2.4% | +1.9% | +1.4% |
| Aug 28 | Jefferies | Maintains | Buy → Buy | — | $6.10 | $6.65 | +9.0% | +9.0% | +1.4% | -1.8% | -0.9% | -0.2% |
| Jan 4 | JP Morgan | Downgrade | Neutral → Underweight | — | $6.78 | $5.05 | -25.5% | -20.2% | -2.9% | -3.0% | -3.7% | +3.7% |
| Jan 4 | Jefferies | Maintains | Buy → Buy | — | $6.78 | $5.05 | -25.5% | -20.2% | -2.9% | -3.0% | -3.7% | +3.7% |
| Oct 26 | Brean Capital | Maintains | Buy → Buy | — | $6.52 | $6.62 | +1.5% | +4.8% | +1.9% | +0.7% | -1.3% | +2.3% |
| Oct 9 | Jefferies | Maintains | Buy → Buy | — | $7.06 | $7.04 | -0.3% | -0.8% | +1.0% | -0.7% | -3.3% | -2.2% |
| Sep 7 | Jefferies | Maintains | Buy → Buy | — | $6.54 | $5.75 | -12.0% | -10.7% | +2.7% | -5.3% | +0.0% | +4.1% |
| Feb 9 | JP Morgan | Maintains | Neutral → Neutral | — | $6.29 | $6.30 | +0.2% | +14.8% | -2.8% | +7.4% | -2.5% | -1.9% |
No insider trades available.
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Services Agreement
ARAY's new services agreement with Dedication Capital likely provides strategic consulting or operational support that could improve efficiency and profitability, warranting attention to implementation success.
Apr 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Accuray's appointment of an experienced Chief Commercial Officer signals management's confidence in accelerating sales growth and market expansion, which could drive revenue acceleration and improve investor sentiment if execution succeeds.
Apr 6
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Sandeep Chalke's departure from Array (ARAY) signals potential leadership instability; investors should monitor whether the separation costs or strategic disagreements impact near-term operations and stock performance.
Mar 19
8-K · 7.01
! Medium
Accuray Incorporated -- 8-K 7.01: Regulation FD Disclosure
Accuray updated its investor presentation on February 17, 2026, providing shareholders with current company information and financial guidance accessible through its investor relations website.
Feb 17
NT 10-Q
!! High
Accuray Incorporated -- Late Quarterly Report -- Distress Signal
Accuray disclosed accounting errors in its remaining performance obligations reporting, requiring a late 10-Q filing and indicating potential internal control weaknesses that investors should monitor closely.
Feb 9
8-K
Accuray Incorporated -- 8-K Filing
Accuray's Q1-Q3 2025 financial statements should no longer be relied upon due to errors in revenue recognition disclosure related to remaining performance obligations (RPO).
Feb 9
8-K
Accuray Incorporated -- 8-K Filing
Accuray faces potential delisting from Nasdaq Global Market and must transfer to Nasdaq Capital Market or risk removal, requiring application submission and fees.
Feb 6
8-K · 7.01
! Medium
Accuray Incorporated -- 8-K 7.01: Regulation FD Disclosure
Accuray will begin presenting updated investor materials to analysts and shareholders beginning February 4, 2026, available on its investor relations website.
Feb 4
Data updated apr 24, 2026 6:43pm
· Source: massive.com